KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments

Personalized Medicine

Volumn 10, Issue 2, 2013, Pages 191-199

  Parsons, Barbara L ^a   Myers, Meagan B ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

ACB PCR; carcinogenesis; colorectal cancer; epidermal growth factor receptor; mutation detection; non small cell lung cancer; oncogene; personalized medicine; polyclonal tumor origin; reactive oxygen species

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ALLELE; ARTICLE; CANCER THERAPY; CELL POPULATION; CODON; COLON TUMOR; DNA SEQUENCE; DOWN REGULATION; DRUG EFFICACY; EPIGENETICS; GENE MUTATION; HUMAN; LUNG TUMOR; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84874606018     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.1     Document Type: Article

References (56)

1. Marchetti A, Milella M, Felicioni L et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 11(10), 1084-1092 (2009).
2. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 16(3), 790-799 (2010).
3. Bando H, Yoshino T, Tsuchihara K et al. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br. J. Cancer 105(3), 403-406 (2011).
4. Parsons BL, Meng F. K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark. Med. 3(6), 757-769 (2009).
5. Garrido-Laguna I, Hong DS, Janku F et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS ONE 7(5), e38033 (2012).
6. Linardou H, Briasoulis E, Dahabreh IJ et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat. Rev. 37(3), 221-233 (2011).
7. Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9(10), 962-972 (2008).
8. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
9. Molinari F, Felicioni L, Buscarino M et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin. Cancer Res. 17(14), 4901-4914 (2011).
10. Khambata-Ford S, Harbison CT, Hart LL et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a Phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 28(6), 918-927 (2010).
11. O'Byrne KJ, Gatzemeier U, Bondarenko I et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the Phase 3 FLEX study. Lancet Oncol. 12(8), 795-805 (2011).
12. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008).
13. Brugger W, Triller N, Blasinska-Morawiec M et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 29(31), 4113-4120 (2011).
14. Myers MB, Wang Y, McKim KL, Parsons BL. Hotspot oncomutations: implications for personalized cancer treatment. Expert Rev. Mol. Diagn. 12(6), 603-620 (2012).
15. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2(1), e17 (2005).
16. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase III INTEREST trial. J. Clin. Oncol. 28(5), 744-752 (2010).
17. Lo RS. Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas. Pharmacogenomics 13(2), 125-128 (2012).
18. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404), 532-536 (2012).
19. Kim MS. Future cancer therapy with molecularly targeted therapeutics: challenges and strategies. Biomol. Ther. 19(4), 371-389 (2011).
20. Bonanno L, Jirillo A, Favaretto A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. Curr. Drug Targets 12(6), 922-933 (2011).
21. McCubrey JA, Steelman LS, Kempf CR et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J. Cell. Physiol. 226(11), 2762-2781 (2011).
22. Alexander S, Friedl P. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol. Med. 18(1), 13-26 (2012).
23. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin. Lung Cancer 13(4), 252-266 (2012).
24. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11(11), 761-774 (2011).
25. Dieterle CP, Conzelmann M, Linnemann U, Berger MR. Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Clin. Cancer Res. 10(2), 641-650 (2004).
26. Parsons BL, Marchant-Miros KE, Delongchamp RR et al. ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. Cancer Invest. 28(4), 364-375 (2010).
27. Mancuso A, Sollami R, Recine F, Cerbone L, Macciomei MC, Leone A. Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy. J. Clin. Oncol. 28(36), e756-e758 (2010).
28. Richman SD, Chambers P, Seymour MT et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal. Cell. Pathol. (Amst.) 34(1-2), 61-66 (2011).
29. Han C, Ma J, Zhao J, Zhou Y, Jing W, Zou H. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis. Cancer Invest. 29, 626-634 (2011).
30. Diaz LA, Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404), 537-540 (2012).
31. Myers MB, Wang Y, McKim KL, McKinzie PB, Parsons BL. The prevalence of KRAS, PIK3CA, and BRAF mutant subpopulations in tumors may be impacting the success of personalized cancer treatment. Cancer Res. 72(8 Suppl. 1), Abstract 1739 (2012).
32. Myers MB, McKim KL, Parsons BL. A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid. Mol. Carcinog. doi:10.1002/mc.21953 (2012) (Epub ahead of print).
33. Lu T, Finkel T. Free radicals and senescence. Exp. Cell Res. 314(9), 1918-1922 (2008).
34. DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. Eur. J. Cancer 45(Suppl. 1), 211-216 (2009).
35. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, Moreno-Sanchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation-why mitochondria are targets for cancer therapy. Mol. Aspects Med. 31(2), 145-170 (2010).
36. Parsons BL. Many different tumor types have polyclonal tumor origin: evidence and implications. Mutat. Res. 659(3), 232-247 (2008).
37. Kizaka-Kondoh S, Tanaka S, Harada H, Hiraoka M. The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv. Drug Deliv. Rev. 61(7-8), 623-632 (2009).
38. Shaw AT, Winslow MM, Magendantz M et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc. Natl Acad. Sci. USA 108(21), 8773-8778 (2011).
39. Coppe JP, Patil CK, Rodier F et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6(12), 2853-2868 (2008).
40. Ferte C, Besse B, Dansin E et al. Durable responses to erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Ann. Oncol. 21(6), 1385-1387 (2010).
41. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada clinical trials group study BR.21. J. Clin. Oncol. 26(26), 4268-4275 (2008).
42. Amatu A, Sartore-Bianchi A, Bencardino K et al. Is codon 13 KRAS mutation biologically different from codon 12 mutation? Curr. Colorectal Cancer Rep. 8, 1-5 (2012).
43. Cespedes MV, Sancho FJ, Guerrero S et al. K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis 27(11), 2190-2200 (2006).
44. Ihle NT, Byers LA, Kim ES et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl Cancer Inst. 104(3), 228-239 (2012).
45. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 85(5), 692-696 (2001).
46. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J. Natl Cancer Inst. 90(9), 675-684 (1998).
47. Humphrey RW, Brockway-Lunardi LM, Bonk DT et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J. Natl Cancer Inst. 103(16), 1222-1226 (2011).
48. Kummar S, Chen HX, Wright J et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat. Rev. Drug Discov. 9(11), 843-856 (2010).
49. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 5(8), 649-659 (2006).
50. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 3(14), 1787-1808 (2011).
51. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting Ras proteins. Genes Cancer 2(3), 359-372 (2011).
52. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J. Thorac. Oncol. 7(8), 1315-1326 (2012).
53. Regulatory watch: FDA guidance on co-developing investigational drugs. Nat. Rev. Drug Discov. 10(2), 86 (2011).
54. Berry RJ, Laing AH, Wells J. Fresh explant culture of human tumours in vitro and the assessment of sensitivity to cytotoxic chemotherapy. Br. J. Cancer 31(2), 218-227 (1975).
55. Freeman AE, Hoffman RM. In vivo-like growth of human tumors in vitro. Proc. Natl Acad. Sci. USA 83(8), 2694-2698 (1986).
56. Kondo J, Endo H, Okuyama H et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl Acad. Sci. USA 108(15), 6235-6240 (2011).